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While medical nutrition therapy is an essential part of the care for critically ill patients, uncertainty 38 
exists about the right form, dosage, timing and route in relation to the phases of critical illness. As 39 
enteral nutrition (EN) is often withheld or interrupted during the ICU stay, combined EN and 40 
parenteral nutrition (PN) may represent an effective and safe option to achieve energy and protein 41 
goals as recommended by international guidelines. We hypothesize that critically ill patients at high 42 
nutritional risk may benefit from such a combined approach during their stay on the intensive care 43 
unit (ICU). Therefore, we aim to test if an early combination of EN and high-protein PN (EN+PN) is 44 
effective in reaching calorie and protein goals in patients at high nutritional risk, while avoiding 45 
overfeeding. This approach will be tested in the here presented EFFORTcombo trial. Nutritionally 46 
high-risk ICU patients will be randomized to either high (≥2.2 mg/kg/d) or low protein 47 
(≤1.2 mg/kg/d). In the high protein group, the patients will receive EN+PN, in the low protein group, 48 
patients will be given EN alone. EN will be started in accordance to international guidelines in both 49 
groups. Efforts will be made to reach nutrition goals within 48–96 hours. The efficacy of the proposed 50 
nutritional strategy will be tested as an innovative approach by functional outcomes at ICU- and 51 
hospital-discharge, as well as at a 6-month follow-up. 52 
Registration:  53 
  EFFORT Trial:   NCT03160547  54 
  EFFORTcombo Trial:  EudraCT-No.: 2018-003703-19 55 
Introduction 56 
During the past decades, the optimal amount of nutrition and route of feeding in critically ill patients 57 
has been debated controversially in the literature(1). It is currently unclear what the optimal protein 58 
energy targets should be and exactly when they should be reached(2). Current international nutrition 59 
guidelines recommend the initiation of medical nutrition therapy in the form of enteral nutrition 60 
(EN) within 24–48 hours in the critically ill patient who is unable to maintain sufficient oral intake(3; 61 
4; 5; 6). However, EN alone is often insufficient to achieve energy and protein targets particularly in 62 
the early phase of critical illness due to frequent interruptions for procedures and metabolic or 63 
gastrointestinal (GI) intolerance(7).  64 
Parenteral nutrition (PN) provides advantages in achieving target nutrition goals earlier, which 65 
might be particularly relevant in patients at high nutrition risk. In fact, the combined use of EN and 66 
PN (EN+PN) may reduce large nutrition deficits in critically ill patients and might be attractive in 67 
those patients who cannot achieve their energy and protein goals during their ICU stay from EN 68 
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alone(8).  One strategy to optimize protein intake is to combine EN and PN (EN+PN) early after 69 
admission to the ICU to reach nutrition targets in patients at nutritional risk as soon as possible. 70 
Another approach would be the early initiation of EN with the addition of supplemental PN if the 71 
nutritional targets cannot be reached by EN alone (SPN) after several days.  72 
For critically ill patients, achieving the protein goal is perhaps more important than achieving the 73 
calorie goal, as several large-scale randomized controlled trials (RCTs) have not been able to 74 
demonstrate any benefit from near goal caloric delivery (9; 10; 11). The few RCTs evaluating protein 75 
targets will be discussed in this manuscript, but clear evidence is still lacking. In fact, determining 76 
the optimal protein dose and timing for critically ill patients is a high priority research question(12). 77 
Even with a combined enteral and parenteral nutrition approach, it may remain challenging to reach 78 
the currently recommended protein goals with available nutrition products. 79 
The EFFORT trial investigates the influence of higher prescription of protein (>2.2 g/kg/day) versus 80 
usual protein prescription (<1.2 g/kg/day) on the outcome of nutritionally-high-risk critically ill 81 
patients(13). One of the biggest challenges in this trial will be continuously achieving adequate 82 
amounts of protein in the higher dose group(14; 15). Since this might be more consistently achieved 83 
through an early combination of EN+PN, we plan to conduct a sub-study in the EFFORT trial wherein 84 
patients randomized to the higher dose group automatically receive combined EN+PN versus EN 85 
alone in the usual care group, known as the EFFORTcombo trial. The purpose of this paper is 86 
therefore to critically review the current evidence, to generate hypotheses and thus, to provide the 87 
scientific rationale for the concept of combining EN+PN applied in the early phase of critical illness 88 
in nutritionally-high risk critically ill patients and to present the details of  trial methods.  89 
Current evidence and discussions about enteral and parenteral 90 
nutrition 91 
EN is the most common route of feeding in the ICU(16) and is uniformly recommended in current 92 
international nutrition guidelines(3; 4; 5; 6). However, recent data demonstrated that EN is still often 93 
withheld or started with significant delay after admission to the ICU in the clinical routine(7; 17). The 94 
progression of EN into a full feed is highly subjective to the clinician(7; 17) and often takes several 95 
days due to feeding intolerance and common interruptions of EN(18; 19; 20). Thus, EN may lead to 96 
protein-calorie deficiency with a possible negative impact on patient outcome– especially in the 97 
patient´s first ICU-week(21; 22; 23). 98 
For years, PN was thought to be associated with neutral or even harmful effects, as older studies 99 
suggested that the risk/benefit ratio for use of PN in the ICU-setting may be much narrower than that 100 
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for use of EN(24; 25). Few studies indicated that the use of PN was associated with more infectious 101 
complications, most likely related to hyperalimentation and hyperglycaemia, as consistently shown 102 
in earlier meta-analyses(26; 27; 28; 29). The “Early Parenteral Nutrition Completing Enteral Nutrition in 103 
Adult Critically Ill Patients (EPaNIC) study by Casaer et al. demonstrated some potentially harmful 104 
effects of early PN in critically ill patients (24; 30; 31; 32; 33). In this study, patients were randomized to 105 
early supplementation of insufficient EN with PN versus withholding PN for one week(24). Patients 106 
in the early PN group received intravenous glucose under conditions of intensive insulin therapy for 107 
the first three days, when EN was still insufficient, and then, if the patient was still in the ICU, PN 108 
was started on day three. In the late PN group, PN was only initiated at day eight. The major findings 109 
demonstrated that early PN led to a prolonged dependency on intensive care treatments and an 110 
increased infection-rates. In contrast, withholding PN improved clinical outcomes, which was 111 
associated with relevant cost saving effects. Importantly, in the large subgroup with a contraindication 112 
for EN upon admission, harm by early PN was even more pronounced, whereas the authors suggested 113 
a suppression of the physiological response mechanism autophagy by feeding in the PN group as 114 
reason for the observed negative effects. Yet, there are several limitations, that limit the validity and 115 
generalizability of the findings. For example, the application of glucose instead of PN under 116 
conditions of tight glycaemic control within the first few days is rather rare at other ICUs. As 117 
evidenced by the primary publication, the harm signal was evident in the early group even before PN 118 
started on day 3, so the harm cannot be attributed to the introduction of PN on day 3. Furthermore, 119 
the majority of patients underwent surgery (90%) and within these 60% cardiac surgery, resulting in 120 
an overall short ICU-stay (3–4 days) with a rather low mortality. Enrolled patients were thus very 121 
low nutritional risk and would not have received any artificial nutrition in many ICUs around the 122 
world. Thus, the results of the EPANIC trial cannot be expanded to nutritionally high-risk patients in 123 
other settings.   124 
Nevertheless, based on the EPaNIC findings and because EN was thought to be cheaper, safer, and 125 
more physiologic, international nutrition guidelines recommend that the enteral route should be 126 
preferably used in critically ill patients without a contraindication to EN (3; 34; 35; 36) and did not support 127 
the routine use of PN in the early phase of critical illness (37). However, the more recent evidence 128 
from randomized studies about the safety and efficacy of PN might make physicians more 129 
comfortable with prescribing PN earlier (38; 39).  130 
The CALORIES trial by Harvey et al. involved 2388 critically ill patients receiving exclusive PN or 131 
EN as soon as possible within 36 hours after admission. No significant differences were found in 132 
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adverse events, mortality or in the infectious complications, demonstrating the equivalence of EN and 133 
PN. However, this study included less severely ill patients(38). More recently, Reignier et al. 134 
investigated the effects of EN vs. PN in the NUTRIREA-2 trial including 2410 patients receiving 135 
invasive mechanical ventilation and vasopressor support for shock(39). In this isocaloric trial, early 136 
EN did not reduce mortality or the risk of secondary infections, but was associated with an increased 137 
risk of digestive complications such as vomiting, diarrhoea and bowel ischemia when compared with 138 
early PN(39). Both the NUTRIREA-2 and CALORIES studies contrasted previously mentioned safety 139 
concerns about PN and overall challenged the paradigm that EN is superior to PN with respect to 140 
clinical outcomes in critical illness. The rather low amount of delivered protein in the EN and PN 141 
group, as well as the short duration of these studies may represent the main reasons why no clinical 142 
advantages could be detected either in the EN or in the PN group.  143 
Given the fact that GI-dysfunction is commonly observed in severely ill patients, and that PN was 144 
demonstrated to be safe in the more recent trials, early high-protein PN may help to securely and 145 
rapidly achieve the recommended nutrition goals during feeding intolerance and GI-symptoms. The 146 
described concerns about EN-safety and EN-progression illuminate a promising opportunity for PN 147 
as alternative nutrition strategy to bridge the gap between the nutritional goals and delivered 148 
calories/proteins, whenever EN is withheld or reduced, at any time point during the ICU stay.  149 
Experience in combining enteral and parenteral nutrition  150 
Pichard and colleagues systemically investigate the concept of EN and PN in the ICU to reduce the 151 
overall nutrition deficiency(40). The pragmatic concept was introduced with the idea to start PN in 152 
patients with proven intolerance to EN and defined as supplemental PN (SPN). In an RCT, patients 153 
who were EN-intolerant, and therefore were unable to reach their nutritional target by day three were 154 
randomized to control group (EN alone) or SPN. Nutritional targets were measured by indirect 155 
calorimetry. Only patients receiving less than 60% of their target during the first three days were 156 
enrolled, therefore leading to a considerable protein-energy debt in all enrolled patients. In this trial, 157 
increased nutritional adequacy and a reduced number of nosocomial infections was observed in the 158 
SPN group(41).  159 
In a different but related concept, the effect of a combined EN+PN strategy was tested in the recent 160 
TOP-UP pilot trial, where PN was started immediately after randomization without testing for EN 161 
intolerance to achieve the prescribed nutrition goals, referred to as combined EN+PN(42). The energy 162 
targets were calculated in a pragmatic approach based on the actual body weight, with the overall 163 
goal to reach the full energy target at day one post randomization. The proposed nutrition strategy 164 
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was feasible and effective regarding the separation of protein-calorie intake between the two groups. 165 
Considering the clinical relevance, no overall benefit could be demonstrated in this small pilot study, 166 
however, the results revealed some encouraging trends of improved functional outcomes in the 167 
combined EN+PN group, which needs to be evaluated in following confirmatory studies. 168 
The most recent EAT-ICU trial tested the effects of an early goal-directed nutrition vs. standard 169 
nutritional care in adult critically ill patients(11). In the early goal-directed nutrition-group, the 170 
nutritional requirements were estimated by indirect calorimetry and 24-hour urinary urea. This group 171 
received an intense EN+PN therapy to cover 100% of the calculated target. Patients randomized to 172 
the control group received standard care, providing 25 kcal/kg/day by EN alone. While the feasibility 173 
of this strategy was demonstrated by a significant separation of both treatment groups with respect to 174 
energy and protein uptake, no significant effect was detected regarding the clinical relevance. 175 
However, frequent hyperglycaemia despite extraordinarily high dosages of administered insulin 176 
demonstrated rather poor metabolic control, which overall might have influenced the evaluated 177 
physical outcome assessment as primary endpoint.  178 
Table 1 gives a short summary of the characteristics of the above-mentioned trials. 179 
What can we learn from recent trials? 180 
Focus on the right patients 181 
One of the reasons why recent trials aiming at high amounts of calories or protein in the ICU-setting 182 
have failed to demonstrate a positive outcome might be inappropriate patient populations. For 183 
example, well-nourished patients following elective surgery, with a short ICU-LOS, such as those 184 
studied in the EPaNIC trial are unlikely to benefit from augmented feeding approaches (or requiring 185 
artificial feeding at all). Critically ill patients are a heterogenous group of patients with respect to the 186 
extent to which they will benefit from artificial nutrition therapy.  187 
The patients` previous nutritional state is of paramount importance as it determines the availability 188 
of self-defence mechanisms such as endogenous antioxidant mechanisms(43; 44). On the other hand, 189 
patients who are either previously malnourished or at risk of malnutrition – either under- or 190 
overweight –, or with expected prolonged ICU-stay will most likely benefit from an intense nutrition 191 
therapy(45; 46; 47; 48; 49). 192 
In extension to the assessment of nutritional risk, increasing attention is paid to the presence of 193 
sarcopenia, frailty and the associated impaired physical functioning, as they have been demonstrated 194 
to be important predictors of a longer ICU- and hospital-length of stay, post-discharge mortality, 195 
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quality of life and lower likelihood to return to home, as summarized in greater detail in recent 196 
reviews(50; 51; 52). Notably, sarcopenic patients might benefit from an intense nutritional therapy, as 197 
recently demonstrated by Koga et al. in a retrospective analysis, where sarcopenic patients supplied 198 
with early EN showed a reduced hospital-mortality compared to those who did not receive early EN, 199 
while that effect was not visible in non-sarcopenic patients(53). 200 
Focus on Protein  201 
The influence of protein on the outcome of critically ill patients has been discussed in controversially 202 
(13; 54), but the above-displayed evidence leads to the conclusion that nutrition interventions targeting 203 
only the energy adequacy did not show statistically significant improvements in many studies. 204 
Increased protein intake however, was associated with improved long-term physical recovery and 205 
lower mortality in observational trials(47; 55; 56; 57) and did not influence duration of renal dysfunction 206 
(58).  207 
One systematic review performed by Davies et al. showed no relationship between protein delivery 208 
and mortality whereas both the low and high protein groups in this review were protein-malnourished 209 
(0.67 g/kg/d and 1.02 g/kg/d)(59). However, even in nutrition trials targeting the adequate provision 210 
of protein, enteral nutrition failed to provide more than 1.5 g/kg day(15), highlighting the need for 211 
high-protein nutrition products or effective strategies to reach the protein goals. Heyland et al recently 212 
performed a meta-analysis assessing the effect of higher vs. lower protein intake but the effect could 213 
not be analysed in detail due to high heterogeneity of the existing trials and incomplete datasets. The 214 
authors were only able to aggregate the effect of higher protein dosing on mortality (risk ratio: 0.89; 215 
95% confidence interval: 0.66–1.19, p= 0.42)(13). Despite the current lack of evidence and 216 
controversial discussion, current guidelines recommend the daily provision of 1.2–2.5 g/kg protein(3; 217 
5; 60). 218 
Focus on functional outcomes 219 
Outcome measures should be patient-cantered, reliable, accurate, and simple to measure in ways that 220 
minimize bias. The majority of large RCTs trials are measuring “hard” outcomes, because they are 221 
objective, comparatively easy to obtain and clearly observable by researchers. Major outcome 222 
parameters, such as mortality have been used in nutrition-trials despite observed decreasing overall 223 
mortality rates and therefore many nutrition trials have remained nonsignificant. Although these 224 
parameters are undoubtedly important, they do not adequately capture the patients’ perspective after 225 
discharge from hospital and might not be sensitive enough for nutrition interventions(61). With the 226 
paradigm “add life to years, not years to life” more and more interventions aim to increase the 227 
quality of life after critically illness (62; 63; 64; 65). In this connection, the evaluation of mid- and long-228 
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term survival by functional outcomes are increasingly considered, because they evaluate muscle 229 
mass, muscle function and physical function closely connected to the patient’s quality of life in the 230 
longer-term(66). Furthermore, functional outcomes reflect the overall state of the patient and are 231 
affected by a variety of treatments, not only nutrition and mobilization. 232 
More recent nutrition studies have used physical outcome assessment, or surrogate parameters and 233 
some have revealed trends of improved functional outcomes intense nutrition therapy groups(11; 16; 42; 234 
67). In addition, Wu et al. observed unchanged “classic” parameters such as hospital-LOS, 235 
postoperative morbidity rates, and standard blood biochemistry profiles, in a patient cohort after 236 
esophagectomy. However, these patients had better physical functioning and less fatigue(68).  237 
On the other hand, physical outcome assessment is complex, and its performance requires adequate 238 
teaching of study sites to receive reliable data for a rigorous knowledge transfer. Poor metabolic 239 
control for example reflected by hyperglycaemia and a low number of patients, might have 240 
confounded the physical outcome assessment as primary endpoint in the EAT-ICU trial(11). 241 
Additionally, the primary endpoint in this study showed some weakness as a) little evidence exists 242 
about its use, as it has rarely been used before, b) the assessment at 6 months after ICU-discharge 243 
bares the risk, that the effects may be influenced by other relevant aspects than the ICU-treatment 244 
itself and c) the physical outcome showed a large variance in the assessment, emphasizing the need 245 
for strict adherence to standardized operation protocols. Based on these findings received from rather 246 
smaller clinical studies,  a well-timed physical outcome assessment matching the study intervention 247 
is encouraged to be evaluated in following confirmatory studies(69).  248 
Conclusion 249 
Based on the evidence gathered from recent trials the authors conclude as follows: 250 
1. Targeting energy adequacy only might not be enough to improve the outcome of critically ill 251 
patients. Increasing attention should be paid on effective supplementation strategies to achieve 252 
recommended protein goals. 253 
2. In iso-energetic trials, the route of administration might not influence “standard” outcome 254 
parameters as mortality and hospital-LOS  255 
3. PN, as well as EN+PN seem to be safe, feasible and effective to achieve the prescribed 256 
nutritional targets in critically ill patients. 257 
4. Without consideration of metabolic tolerance, early aggressive EN+PN may not be effective 258 
in improving patient outcomes in unselected patients. 259 
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5. In nutritionally high-risk patients, combined EN+PN may improve functional and other 260 
patient-reported outcomes. 261 
From the EFFORT trial to the EFFORTcombo trial 262 
Based on our review of the current evidence, we hypothesize that a combination of EN+high-protein-263 
PN vs. EN alone in nutritionally high-risk patients can improve the functional outcomes. To test this 264 
hypothesis, we plan the nested sub-study “EFFORTcombo” in the context of the EFFORT trial. 265 
The EFFORT Trial (clinicaltrials.gov/NCT03160547) was developed as multi-centre pragmatic 266 
volunteer driven, registry based RCT in which 4000 patients will be randomly assigned to either a 267 
higher prescribed dose of protein (≥2.2 g/kg/d) or usual protein prescription (≤1.2 g/kg/d) (13). 268 
However, the EFFORT trial does not specify how these determined protein dosages can be achieved. 269 
As protein delivery has been challenging in the past and only 55% of prescribed protein (equal to 270 
0.7 g/kg/d) are actually delivered as reported in the International Nutrition Survey (INS)(14), we 271 
propose that the addition of high-protein-PN to EN compared to EN alone, represents a promising 272 
nutrition strategy to increase nutritional adequacy to achieve the goals set in the original EFFORT 273 
trial. In comparison to the EFFORT trial, in the proposed multicenter EFFORTcombo substudy a) 274 
patients randomized to the high protein dosage will receive a combination of high-protein PN and EN 275 
and b) the main outcome for this substudy is short-term physical function as assessed by the six-276 
minute walk test.  277 
In addition, we will use a high-protein PN product and thus expect to reach the nutrition goals faster 278 
and more securely through this combination as shown in Figure 1. We hypothesize that the augmented 279 
protein delivery to these nutritionally high-risk-patients will translate into improved functional and 280 
patient-reported outcomes. Written informed consent will obtained from all patients or their legal 281 
representatives before enrolment. The ethic committee of the RWTH Aachen University approved 282 
the study (EK339/19) and local jurisdictional approval will be obtained for each centre. 283 
Inclusion and exclusion criteria 284 
As a nested sub-study within the EFFORT trial, the EFFORTcombo study includes mechanically 285 
ventilated critically ill adult patients (≥18 years), who are at high nutritional risk as defined in detail 286 
in our published EFFORT protocol(13). Table 2 illustrates in detail all in- and exclusion criteria.  287 
Investigational high-protein product 288 
To provide high-protein-PN in patients randomized to the EN+PN group, we will use Olimel® N12 289 
with electrolytes provided by Baxter® International Inc. Olimel is a 3-in-1 parenteral admixture 290 
solution containing the following drug substances: dextrose solution, amino acid solution with 291 
10 
 
electrolytes (sodium, potassium, magnesium, phosphate) and lipid emulsion with an olive oil/soybean 292 
oil ratio of 80:20 and 12 g nitrogen per litre. This product will be similar in energy density to the 293 
standard EN solutions (1–1.4 kcal/ml). Olimel® N12 will be administered via central venous line 294 
until the daily target of ≥2.2 g/kg/d is reached.  295 
Peri-Olimel is a PN-product that can be used either peripherally or centrally and will be used 296 
whenever a central venous line for PN is not available. Both products are indicated for parenteral 297 
nutrition for adults. 298 
Nutrition protocol 299 
As soon as the patient is hemodynamically stable and there is a nasogastric tube or feeding tube in 300 
place, EN will be started within 24–48 hours after admission to ICU, as per local standards. If the 301 
patient has not been started on EN but there is an indication and intention to start on EN in the first 302 
7 days, the patient will still be considered eligible for this study. The type of enteral formula should 303 
be of similar caloric density (1–1.5 kcal/ml), but otherwise used in accordance to local standards. In 304 
both groups, targets will be set using pre-ICU known weight (e.g. dry actual weight). For patients 305 
with BMI >30 kg/m2, ideal body weight based on a BMI of 25 kg/m2 will be used. As per current 306 
guidelines, we recommend monitoring for metabolic and GI-tolerance as well as the provision of 307 
usual nutritional therapy by credentialed clinicians with expertise in directing the feeding of critically 308 
ill patients. If equipoise regarding the nutritional regimen or protein dosage is not given in the 309 
clinician’s prescription for an individual patient, the patient will not be included in the trial. 310 
Metabolic and feeding tolerance will be assessed by blood glucose, insulin dose, glucose infusion 311 
rates, phosphate, urea, triglycerides and electrolytes, which will be monitored frequently, as clinically 312 
indicated and consideration of recent guidelines for monitoring of nutrition therapy will be endorsed 313 
(70).  314 
Those patients randomized into the high-protein group will receive EN+PN, with PN added as soon 315 
as possible following randomization. While the identification and randomization of appropriate 316 
patients will take 24-48 hours, the PN should be started within 48-96 hours. The study PN solution 317 
will be started at 25 ml/hr and increased if tolerated (e.g. the infusion rate can be increased by 25 ml 318 
every 4–6 hours) so that >80% of protein nutrition goals will be reached within 48–96 hours of 319 
starting PN. We aim to avoid overfeeding calories and if the protein target cannot be met by combined 320 
EN+PN, protein supplements (enteral protein supplements or intravenous amino acids) should be 321 
added as per local standards to reach the goal of ≥2.2 g/kg/d. The PN-rate will be adjusted in a 322 
compensatory fashion to ensure that patients receive >80% of their target goal rate on a continuous 323 
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basis, for example if EN infusion rates change due to GI-intolerance or interruption. Therefore, PN 324 
should be continued for a minimum of 7 days even at a minimal rate (10 ml/h).  325 
Both EN and PN will be continued for a minimum of 7 days post randomization and be continued 326 
on the ward. PN should be continued at a minimum of 10 ml/h until the 7th day to enable easy 327 
compensations of the fluctuation in oral nutrition and/or EN-rates as well on the normal ward. The 328 
EN-rate will be always adjusted to the individual patients, while considering the minimum PN-rate 329 
of 10 ml/h. At 7 days post randomization, if the patient is still in the ICU, and PN is clinically 330 
indicated to achieve high-protein goals, Olimel® N12E will be used in the high dose group. In the 331 
low dose group, if a patient develops a contraindication to EN, after day 7, PN can be used with 332 
product selection and duration determined by local standards but protein goals should not be above 333 
1.2 g/kg/day. In either group, after the end of the 7 days post randomization study period, if the patient 334 
has been discharged from the ICU and PN is clinically indicated, standard PN solutions can be used. 335 
Olimel® N12E will be discontinued at ICU-discharge (unless it occurs before day 7 as explained 336 
below), day 28 (maximum of PN treatment if the patients are still on ICU), or until death, whichever 337 
comes first.  338 
The primary endpoint - functional outcome assessment 339 
The primary objective of this sub-study is to demonstrate improved short-term physical function by 340 
a 6-minute walk test at hospital discharge. We also will assess in-hospital secondary outcomes and 341 
patient-reported 6-month outcomes similar to the NEXIS trial (Clinicaltrials.gov, NCT03021902). 342 
These secondary outcomes include the overall strength of upper and lower extremity (Medical 343 
Research Council sum score), quadriceps- and handgrip-strength (dynamometry), body composition 344 
(ultrasound and available CT-scans), overall physical function (Short Physical Performance Battery 345 
and Functional Status Score for the ICU), which will be assessed longitudinally while the patient is 346 
still in the hospital. The physical functioning (Katz activities of daily living and Lawtons instrumental 347 
activities of daily living) as well as health related quality of life (Short Form-36 and EQ-5D5L) will 348 
be assessed while the patient is in the hospital and 6 months after discharge. All outcome assessment 349 
will be performed by trained outcome assessors strictly following detailed standard operating 350 
protocols. All assessors will be blinded to the treatment group.  351 
Summary  352 
Taken together, international observational studies revealed considerable practice variations, and the 353 
existing clinical trial data, albeit weak and outdate, did not always support the routine use of PN in 354 
the early phase of critical illness. Importantly, the more recent evidence about the safety and efficacy 355 
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of PN might make physicians more comfortable with prescribing PN earlier to bridge the gap between 356 
nutrition goals and actual delivery of calories and protein. This might be especially for patients at 357 
high nutritional risk, or patients with an increased risk for prolonged ICU-stay. In this context, we are 358 
proposing the EFFORTcombo trial that evaluates the effects of an early combined EN + high-protein 359 
PN nutrition strategy to decrease the nutritional deficiencies in the critically ill patients at nutritional 360 
risk. We hypothesize that this nutritional strategy will improve the functional outcomes of these 361 
nutritionally high-risk patients.  362 
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Table 1: Comparison of recent trials combining enteral nutrition and parenteral nutrition, abbreviations: EN= enteral nutrition, PN= 408 
parenteral nutrition, SPN= supplemental parenteral nutrition, EGDN=early goal directed nutrition, BMI= body mass index, BW= 409 
body weight IBW= ideal body weight, APACHE II= Acute Physiology and Chronic Health Evaluation II Score, SAPS II= Simplified 410 
Acute Physiology II Score, SOFA= Sequential Organ Failure Assessment Score 411 
Trial Heidegger 2013 (41) Wischmeyer (42) Allingstrup 2017 (11) 
Trial focus EN vs. SPN EN vs. EN+PN in over- or 
underweight patients 
EGDN vs. standard of care 
PN to reach target: 
• EGDN group: <24 hours  
• Standard group: > 7 days  
Enrolled 
patients 
305 125 203 
Mean Age in 
years 




(52% BMI < 25  







• APACHE II Score= 22.5 
• SAPS II = 48 
• APACHE II Score= 20.7 
• SOFA= 6 
• SAPS II Score =47.5 
• SOFA Score =8 
Calculation 
of Energy 
• 25 kcal/kg/d (for 
women) and 30 
kcal/kg/d (for men),  
using IBW or 
anamnestic BW for 
patients with a BMI ≤ 20 
• Indirect calorimetry in 
65% of patients 
• BMI <25: ≥25 kcal/kg/d 
actual BW 
• BMI > 35: ≥20 kcal/kg/d 
adjusted BW (= IBW + 
[actual weight – IBW] x 
0.25, where IBW is 
based on a BMI of 25) 
• EGDN group: indirect 
calorimetry  





• SPN group: 28 kcal/kg/d 
(103%) 
• EN group: 20 kcal/kg/d 
(77%) 
First 7 days:  
• EN+PN group: 95%  
• EN group: 68%  
First 27 days: 
• EN+PN: 90% of target 
• EN group: 67% of target  
• EGDN group: 97%  
• Standard group: 64%  
 
Calculation 
of protein  
1–2 g/kg/d using IBW ≥1.2/kg/d  
Using actual body weight 
for patients with BMI <25 
and adjusted body weight 
for patients with BMI >35 
• EGDN group: ≥1.5 
g/kg/day, calculated by 
urea excretion using 
Bistrian´s equation 




Not reported First 7 days:  
• EN+PN: 86% of target 
• EN group: 61% of target 
First 27 days: 
• EN+PN: 82% of target 
• EN group: 60% of target 
 
• EGDN group: 97%  




Table 2: In- and exclusion Criteria - comparison between EFFORT and EFFORTcombo, modified from (13) 413 
Inclusion Criteria for the EFFORT and EFFORTcombo trials 
• ≥18 years old 
• Nutritionally high-risk:  
o Low (≤25) or high BMI (≥35) 
o Moderate to severe malnutrition (as defined by local assessments) 
o Frailty (Clinical Frailty Scale, ≥5 or more) 
o Sarcopenia (SARC-F score, ≥4 or more) 
o From point of screening, projected duration of mechanical ventilation >4 days. 
• Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation 
>48 hours 
Exclusion Criterion Rationale for Exclusion 
Criteria from the original EFFORT trial 
>96 continuous hours of mechanical ventilation before 
screening 
Intervention is likely most effective when 
delivered early 
Expected death or withdrawal of life-sustaining treatments 
within 7 days from screening  
Patients unlikely to receive benefit 
Pregnancy Unknown effect on the fetus 
The responsible clinician feels that the patient either needs 
low or high protein  
Uncertainty about protein dosage does not exist, 
patient safety issues 
Patient requires PN only, and sites do not have the products 
to reach the high-dose protein group 
Site will be unable to reach high-protein-dose 
prescription 
Additional criteria in EFFORTcombo 
Patients in hospital >5 days prior to ICU admission or 
severe pre-existing weakness 
Confounding of results 
Pre-existing severe neuromuscular, cognitive or language 
impairment 
Patient will be unable to perform physical 
outcome assessment 
Lower extremity impairments that prevents the patient from 
walking (previously or newly acquired) 
Patient will be unable to perform physical 
outcome assessment 
Absolute contraindication to EN Randomization impossible 
Severe metabolic disorders including electrolyte disorders, 
uncontrolled hyperglycaemia, hyperlipidaemia, 
hypophosphatemia, or impaired nitrogen utilization 
Intervention potentially hazardous 
Severe chronic liver disease (MELD-score >20) or acute 
fulminant hepatitis. 
Protein supplementation may be harmful in 
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